Skip to main content
OpenTrials
Completed

NCT Number: NCT02196220

Ultrasonographic Assessment of Carpal Tunnel Syndrome

Mucopolysaccharidosis are lysosomal storage disorders such as Hunter, Hurler, and Sanfilippo syndromes. These patients have a genetic enzyme deficiency that results in the inability to degrade glycosaminoglycans. The glycosaminoglycans accumulate in lysosomes causing cell enlargement and subsequent dysfunction. The accumulation occurs in all tissues including cartilage, joint capsule, and tendons and can lead to carpal tunnel syndrome, trigger digits, and various other orthopaedic manifestations [Van Heest, White]. These children often suffer from severe cognitive impairment and are often unable to communicate pain or numbness. Carpal tunnel syndrome is almost always present, but may not become apparent until symptoms are severe and loss of function has occurred. The current gold standard for diagnosis consists of electromyographic (EMG) and nerve conduction velocity (NCV) studies under sedation or general anesthetic [Khanna].

Primary Objective: The investigators plan to correlate EMG findings and median nerve cross-sectional area in children with mucopolysaccharidosis. The investigators hypothesis is that ultrasonography of the carpal tunnel in patients with mucopolysaccharidosis will prove to be an effective, reliable, and safe method to evaluate the median nerve, thus avoiding the need for EMG studies and anesthesia.

Secondary Objective: The investigators want to determine the cross-sectional area of the median nerve using ultrasonography in a cohort of healthy children, ages 3-12. The investigators plan to evaluate a cohort of healthy children to determine a normal cross-sectional area of the median nerve.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–12 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Utah/Primary Children's Medical Center

Salt Lake City, Utah, 84121, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For the first arm of the study (25 participants):

  • Children with mucopolysaccharidosis presenting to the senior author's clinic with signs or symptoms of carpal tunnel syndrome will be enrolled to receive both an EMG and carpal tunnel ultrasound of the upper extremities.

For the second arm of the study (100 participants):

  • Healthy children ages 3-12 with no acute upper extremity trauma or history of mucopolysaccharidosis.
  • 25 additional participants requested in case of inconclusive ultrasound results, patient removal, or other unusable results.

Exclusion criteria

First arm:

  • Children with mucopolysaccharidosis who have undergone previous treatment for carpal tunnel syndrome.

Second arm:

  • Acute (<3month) wrist or hand surgery/injuries.
  • Unable to obtain parental consent or patient assent.
  • History of mucopolysaccharidosis.
  • Non-english speaking.
  • Cognitive impairment.

Treatment and study plan

Primary outcomes

  1. Median nerve cross-sectional area in children with mucopolysaccharidosis and a cohort of healthy children, ages 3-12.

    Time frame: 6-weeks after open carpal tunnel release

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Registry information

Official study title

Ultrasonographic Assessment of Carpal Tunnel Syndrome in Children With Mucopolysaccharidosis and Comparison to Median Nerve Anatomy in Healthy Children.

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Jul 21, 2014
Registry last updated
Aug 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.